Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;31(12):e16522.
doi: 10.1111/ene.16522. Epub 2024 Oct 22.

Intensive care due to myasthenia gravis: Risk factors and prognosis

Affiliations

Intensive care due to myasthenia gravis: Risk factors and prognosis

Chris Myllynen et al. Eur J Neurol. 2024 Dec.

Abstract

Background and purpose: Exacerbation of myasthenia gravis (MG) with respiratory failure requires intensive care. We aimed to study the risk factors for intensive care unit admission for MG exacerbation and myasthenic crisis (MC) and the prognosis of people with MG (pwMG) thereafter.

Methods: This retrospective study investigated patients in the Helsinki and Uusimaa hospital district during the years 2008-2021. PwMG (International Classification of Diseases, 10th revision code G70.0) were identified through a data repository search, followed by a chart review of patient records. Risk factors for intensive care due to MG exacerbation were evaluated as compared with the patients only treated in the outpatient clinic and those treated in the neurological ward for MG exacerbation. The outcomes of patients in intensive care for any reason were also compared with those of patients in intensive care for exacerbation of bronchial asthma.

Results: Of 577 pwMG, 35 (6.1%) needed intensive care for MG within a median of 5.3 months from diagnosis. The mean (±SD) age at MG diagnosis was higher in the intensive care group (60.5 [±16.1] years) compared to the outpatient (48.3 [±20.9] years; p < 0.001) and neurological ward groups (53.4 [±20.8] years; p = 0.044). Thymoma (odds ratio [OR] 4.8, 95% confidence interval [CI] 1.19-19.43; p = 0.028) and female sex (OR 2.1, 95% CI 1.02-4.48; p = 0.045) were independent risk factors for intensive care. In-hospital mortality was 4% for MC patients. Six-month mortality after intensive care for MG exacerbation (14.3%) was twice that for asthma exacerbation (7.7%).

Conclusion: Our study shows an increased risk of intensive care treatment for patients with late-onset MG, female sex or thymoma, occurring usually within 6 months from diagnosis, which emphasises the importance of early treatment choices.

Keywords: exacerbation; intensive care; myasthenia gravis; myasthenic crisis; risk factors.

PubMed Disclaimer

Conflict of interest statement

Anni Tuulasvaara declares travel expenses from UCB Pharma. Sini Laakso declares travel expenses from UCB Pharma, lecture fees from Argenx, and advisory fees from UCB Pharma, Argenx and Alexion. The remaining authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Study subgroups. Flow chart showing data acquisition and formation of the study subgroups. The main subgroups of the study are highlighted. There was partial overlap between people with myasthenia gravis (pwMG) in intensive care for reasons other than myasthenia gravis (MG) and hospital ward groups; some pwMG in intensive care for MG also had episodes in regular or neurological wards. The total number 577 of pwMG included the intensive care group, neurological ward group, outpatient care group, and patients in regular wards, to exclude duplicates. In intensive care for other reasons were 99 of 167 pwMG who did not come up in other groups, and they were excluded from the comparisons due to the possibility of MG affecting the intensive care admission. MC, myasthenic crisis.

References

    1. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023‐1036. - PubMed
    1. Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020;11:212. - PMC - PubMed
    1. Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):176‐188. - PubMed
    1. Baggi F, Andreetta F, Maggi L, et al. Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology. 2013;80:188‐195. - PubMed
    1. Claytor B, Cho SM, Li Y. Myasthenic crisis. Muscle Nerve. 2023;68(1):8‐19. - PubMed